Clinical Trials Logo
  1. Home
  2. Eosinophilia
  3. NCT04018118

Natural History of Hypereosinophilia and Hypereosinophilic Syndromes — COHESION  

Hypereosinophilic Syndrome Clinical Trial

Official title:
Study of Clinical Profiles of Patients Followed for Chronic Hypereosinophilia and/or Hypereosinophilic Syndrome by the Creation of a National Cohort

Clinical Trial Summary

Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments. Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)

Clinical Trial Description

There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles: A. a single flare-up of their disease, with favourable evolution spontaneously or under corticosteroid therapy, without further recurrence B. recurrent flare-ups with a variable free interval of several months to several years, with or without persistent eosinophilia between flare-ups C. a chronic disease requiring the continuation of a substantive treatment D. chronic asymptomatic HE for years: the mechanisms involved in the occurrence of possible organ damage are unknown The primary objective of the study is to describe the frequency of the different clinical manifestations during the diagnostic and follow-up of the hypereosinophilic syndrome (HES). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to eosinophilia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04018118
Study type Observational
Source University Hospital, Lille
Contact Guillaume Lefevre, MD
Phone 03 20 44 55 72
Email Guillaume.lefevre@chru-lille.fr
Status Recruiting
Phase
Start date May 6, 2019
Completion date May 2031
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05334368 - Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial Phase 3
Recruiting NCT00044304 - Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Phase 2
Completed NCT00097370 - Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Phase 3
Completed NCT00171912 - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Phase 2
Terminated NCT00171860 - A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Phase 2
Recruiting NCT02581514 - Eosinophilia Diagnosis N/A
Completed NCT00787384 - Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Phase 2
Recruiting NCT03801434 - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Phase 2
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Completed NCT03306043 - A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Phase 3
Completed NCT02836496 - Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Phase 3
Completed NCT00086658 - Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Phase 3
Recruiting NCT00276926 - Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Phase 2
Active, not recruiting NCT02101138 - Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Phase 2
Recruiting NCT00091871 - A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Completed NCT01713504 - Identification of New Markers in the Hypereosinophilic Syndrome N/A
Completed NCT00017862 - Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Phase 2
Completed NCT00038675 - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate N/A
Terminated NCT00230334 - Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Phase 2
Recruiting NCT04191304 - A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) Phase 3